Sun Pharmaceutical Industries Limited
SUNPHARMA
Rang in Aktien
#520
Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical... Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical enterprise, is dedicated to the research, development, production, and marketing of both proprietary and unbranded medicinal formulations, alongside active pharmaceutical ingredients (APIs), for distribution across India and international markets. Its extensive product range encompasses treatments for numerous therapeutic fields, including central nervous system disorders, dermatological conditions, cardiovascular diseases, oncology, ophthalmic care, neuropsychiatry, gastrointestinal issues, infectious diseases, diabetes management, pain relief, nutritional supplements, respiratory ailments, gynaecology, urology, orthopaedics, nephrology, and dental health, among others. The company additionally provides APIs crucial for the creation of anti-cancer drugs, peptides, steroids, sex hormones, and controlled substances. Its generic medications are available in various forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquid preparations. Furthermore, Sun Pharma develops specialized medications and a variety of over-the-counter health products. The company was established in 1983 and operates from its headquarters in Mumbai, India.
Aktienkurs
$19.24
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$46.15B
Veränderung (1 Tag)
-0.97%
Veränderung (1 Jahr)
0.11%
Land
IN
Handel Sun Pharmaceutical Industries Limited (SUNPHARMA)
Kategorie
Healthcare
Gewinn für Sun Pharmaceutical Industries Limited (SUNPHARMA)
Gewinn im Jun 2026 TTM: $1.76B
Laut den aktuellen Finanzberichten von Sun Pharmaceutical Industries Limited betragen die aktuellen Gewinne des Unternehmens $1.76B. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $1.33B, eine Steigerung gegenüber dem Gewinn im Jahr 2023, der $1.14B betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Sun Pharmaceutical Industries Limited von 2004 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $1.76B | 9.86% |
| 2025 | $1.61B | 21.21% |
| 2024 | $1.33B | 16.34% |
| 2023 | $1.14B | 93.65% |
| 2022 | $588.17M | 54.49% |
| 2021 | $380.72M | -42.58% |
| 2020 | $663.01M | 20.88% |
| 2019 | $548.49M | 3.41% |
| 2018 | $530.42M | -62.03% |
| 2017 | $1.40B | 40.80% |
| 2016 | $992.01M | -3.13% |
| 2015 | $1.02B | 33.99% |
| 2014 | $764.30M | -3.90% |
| 2013 | $795.33M | 20.15% |
| 2012 | $661.93M | 44.90% |
| 2011 | $456.82M | 45.01% |
| 2010 | $315.02M | -17.95% |
| 2009 | $383.94M | -3.94% |
| 2008 | $399.69M | 107.87% |
| 2007 | $192.27M | 43.47% |
| 2006 | $134.02M | 39.03% |
| 2005 | $96.39M | 9.76% |
| 2004 | $87.82M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| - | - |
CN
|
